Index -
P/E 72.59
EPS (ttm) 1.07
Insider Own 2.01%
Shs Outstand 188.60M
Perf Week -4.28%
Market Cap 14.73B
Forward P/E 29.09
EPS next Y 2.67
Insider Trans -5.68%
Shs Float 186.06M
Perf Month -13.89%
Income 205.46M
PEG 1.69
EPS next Q 0.33
Inst Own 99.32%
Short Float 2.10%
Perf Quarter -12.63%
Sales 2.48B
P/S 5.95
EPS this Y 98.28%
Inst Trans 2.04%
Short Ratio 2.45
Perf Half Y -10.91%
Book/sh 26.74
P/B 2.90
EPS next Y 54.58%
ROA 3.09%
Short Interest 3.91M
Perf Year -15.94%
Cash/sh 5.51
P/C 14.07
EPS next 5Y 43.00%
ROE 4.22%
52W Range 76.02 - 99.56
Perf YTD -19.56%
Dividend Est. -
P/FCF 81.00
EPS past 5Y -
ROI 3.63%
52W High -22.10%
Beta 0.32
Dividend TTM -
Quick Ratio 1.70
Sales past 5Y 10.23%
Gross Margin 76.81%
52W Low 2.03%
ATR (14) 2.11
Dividend Ex-Date -
Current Ratio 2.74
EPS Y/Y TTM 183.46%
Oper. Margin 8.60%
RSI (14) 32.11
Volatility 2.43% 2.59%
Employees 3401
Debt/Eq 0.22
Sales Y/Y TTM 16.45%
Profit Margin 8.30%
Recom 1.74
Target Price 108.06
Option/Short Yes / Yes
LT Debt/Eq 0.12
EPS Q/Q 75.38%
Payout 0.00%
Rel Volume 2.15
Prev Close 76.97
Sales Surprise -0.46%
EPS Surprise 47.53%
Sales Q/Q 9.61%
Earnings Apr 24 AMC
Avg Volume 1.59M
Price 77.56
SMA20 -6.76%
SMA50 -9.41%
SMA200 -12.51%
Trades
Volume 3,433,406
Change 0.77%
Date
Action
Analyst
Rating Change
Price Target Change
May-17-24 Downgrade
Robert W. Baird
Outperform → Neutral
$104 → $72
May-14-24 Initiated
Evercore ISI
Outperform
$113
Nov-15-23 Initiated
Wells Fargo
Overweight
$100
Oct-23-23 Upgrade
Bernstein
Underperform → Mkt Perform
$82
Sep-28-23 Initiated
Raymond James
Mkt Perform
Sep-18-23 Initiated
UBS
Buy
$120
Jul-27-23 Initiated
Scotiabank
Sector Perform
$95
Jul-05-23 Upgrade
BMO Capital Markets
Market Perform → Outperform
$102
Jun-14-23 Resumed
Credit Suisse
Outperform
$120
Mar-21-23 Initiated
Bernstein
Underperform
$81
Feb-22-23 Downgrade
Oppenheimer
Outperform → Perform
Feb-21-23 Initiated
Citigroup
Neutral
$116
Jan-30-23 Initiated
BMO Capital Markets
Market Perform
$107
Jan-18-23 Initiated
Canaccord Genuity
Hold
$119
Oct-31-22 Upgrade
Oppenheimer
Perform → Outperform
$92 → $110
Jul-13-22 Initiated
Cantor Fitzgerald
Overweight
$110
Jun-13-22 Resumed
Wedbush
Neutral
$146 → $70
Apr-25-22 Upgrade
Morgan Stanley
Equal-Weight → Overweight
$96 → $113
Nov-22-21 Upgrade
William Blair
Mkt Perform → Outperform
Oct-07-21 Resumed
Jefferies
Buy
$100
Show Previous Ratings
Today 05:06AM
May-15-24 07:00AM
May-13-24 04:14PM
May-09-24 06:15AM
May-08-24 08:00AM
07:00PM
Loading…
May-06-24 07:00PM
04:47PM
May-04-24 04:00PM
May-03-24 02:31PM
Apr-29-24 02:26PM
Apr-27-24 05:06AM
01:07AM
Apr-26-24 08:49AM
06:53AM
Apr-25-24 01:30PM
11:48AM
Loading…
11:48AM
11:44AM
10:47AM
10:31AM
07:39AM
06:46AM
(Thomson Reuters StreetEvents)
03:19AM
Apr-24-24 06:30PM
05:33PM
05:15PM
04:23PM
04:14PM
(Associated Press Finance)
04:03PM
Apr-23-24 11:36AM
Apr-22-24 04:26PM
09:16AM
Loading…
09:16AM
Apr-17-24 10:01AM
Apr-12-24 07:00PM
Apr-10-24 08:00AM
Apr-01-24 07:01PM
Mar-17-24 08:50AM
Mar-16-24 05:06AM
Mar-12-24 08:30AM
Mar-11-24 10:00AM
Mar-08-24 01:31AM
Mar-07-24 08:30AM
Mar-01-24 09:00AM
Feb-27-24 12:03AM
Feb-26-24 02:36PM
02:12PM
Feb-23-24 04:29PM
12:33PM
11:34AM
07:21AM
(Thomson Reuters StreetEvents)
05:43AM
04:25AM
Feb-22-24 06:00PM
05:15PM
04:42PM
04:23PM
(Associated Press Finance)
04:03PM
Feb-19-24 09:15AM
Feb-15-24 10:00AM
Feb-13-24 01:10PM
Feb-08-24 04:10PM
08:00AM
Feb-07-24 05:21AM
Feb-06-24 08:30AM
Jan-24-24 11:21AM
Jan-23-24 08:00AM
Jan-20-24 05:06AM
Jan-15-24 09:45AM
Jan-10-24 06:16PM
Jan-03-24 08:00AM
Dec-21-23 06:14AM
Dec-20-23 05:08PM
04:05PM
Dec-14-23 07:05PM
Dec-05-23 11:01AM
Dec-02-23 05:06AM
Dec-01-23 11:31AM
Nov-29-23 09:13PM
06:30AM
Nov-28-23 11:09AM
08:30AM
Nov-16-23 08:47AM
Nov-10-23 12:58AM
Nov-09-23 04:43PM
03:49AM
Nov-08-23 05:19AM
Nov-07-23 07:09PM
(Morningstar Research) +12.16%
05:07PM
(Investor's Business Daily)
02:24PM
Nov-06-23 07:20PM
Nov-04-23 05:06AM
Nov-03-23 01:23AM
Nov-02-23 05:02PM
12:17PM
08:44AM
07:15AM
Nov-01-23 06:30PM
05:55PM
05:02PM
(Associated Press Finance)
04:05PM
04:02PM
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
BIENAIME JEAN JACQUES Director May 10 '24 Option Exercise 63.10 20,000 1,262,000 494,994 May 13 03:57 PM BIENAIME JEAN JACQUES Director May 10 '24 Sale 81.14 20,000 1,622,800 474,994 May 13 03:57 PM BIENAIME JEAN JACQUES Director May 09 '24 Option Exercise 63.10 20,000 1,262,000 494,994 May 13 03:57 PM BIENAIME JEAN JACQUES Director May 09 '24 Sale 81.62 20,000 1,632,400 474,994 May 13 03:57 PM Davis George Eric EVP, Chief Legal Officer May 02 '24 Option Exercise 63.10 1,850 116,735 58,007 May 06 04:45 PM Ajer Jeffrey Robert EVP, Chief Commercial Officer May 02 '24 Sale 82.91 5,000 414,550 66,767 May 06 04:40 PM Davis George Eric EVP, Chief Legal Officer May 02 '24 Sale 85.01 1,850 157,268 56,157 May 06 04:45 PM BIENAIME JEAN JACQUES Director Apr 12 '24 Option Exercise 63.10 20,000 1,262,000 494,994 Apr 15 04:21 PM BIENAIME JEAN JACQUES Director Apr 12 '24 Sale 91.26 20,000 1,825,200 474,994 Apr 15 04:21 PM BIENAIME JEAN JACQUES Director Apr 11 '24 Option Exercise 63.10 20,000 1,262,000 494,994 Apr 15 04:21 PM BIENAIME JEAN JACQUES Director Apr 11 '24 Sale 90.99 20,000 1,819,800 474,994 Apr 15 04:21 PM Burkhart Erin GVP, Chief Accounting Officer Apr 10 '24 Sale 90.00 2,286 205,740 16,156 Apr 12 03:07 PM Davis George Eric EVP, Chief Legal Officer Mar 28 '24 Sale 88.34 24,602 2,173,341 55,856 Apr 01 04:54 PM Slamon Dennis Director Mar 18 '24 Option Exercise 79.70 10,000 797,000 40,809 Mar 20 05:13 PM BIENAIME JEAN JACQUES Director Mar 06 '24 Sale 86.71 1,000 86,713 560,203 Mar 07 05:35 PM FUCHS HENRY J President, Worldwide R&D Mar 05 '24 Sale 85.18 35,341 3,010,396 212,117 Mar 07 06:54 PM Ajer Jeffrey Robert EVP, Chief Commercial Officer Mar 05 '24 Sale 87.07 4,000 348,280 94,047 Mar 07 05:32 PM BIENAIME JEAN JACQUES Director Mar 05 '24 Sale 85.51 1,000 85,510 561,203 Mar 07 05:35 PM BIENAIME JEAN JACQUES Director Feb 27 '24 Sale 90.35 1,000 90,350 562,203 Feb 29 05:05 PM BIENAIME JEAN JACQUES Director Feb 09 '24 Option Exercise 63.10 15,000 946,500 434,602 Feb 12 05:20 PM BIENAIME JEAN JACQUES Director Feb 09 '24 Sale 88.28 15,000 1,324,200 419,602 Feb 12 05:20 PM BIENAIME JEAN JACQUES Director Feb 08 '24 Option Exercise 63.10 15,000 946,500 434,602 Feb 12 05:20 PM BIENAIME JEAN JACQUES Director Feb 08 '24 Sale 89.77 15,000 1,346,550 419,602 Feb 12 05:20 PM BIENAIME JEAN JACQUES Director Jan 10 '24 Option Exercise 63.10 10,000 631,000 435,162 Jan 11 02:40 PM BIENAIME JEAN JACQUES Director Jan 10 '24 Sale 96.38 10,000 963,800 425,162 Jan 11 02:40 PM BIENAIME JEAN JACQUES Director Jan 09 '24 Option Exercise 63.10 10,000 631,000 435,162 Jan 11 02:40 PM BIENAIME JEAN JACQUES Director Jan 09 '24 Sale 98.19 10,000 981,900 425,162 Jan 11 02:40 PM BIENAIME JEAN JACQUES Director Dec 21 '23 Option Exercise 63.10 10,000 631,000 435,112 Dec 22 05:14 PM BIENAIME JEAN JACQUES Director Dec 21 '23 Sale 93.99 10,000 939,900 425,112 Dec 22 05:14 PM Davis George Eric EVP, Chief Legal Officer Dec 13 '23 Sale 95.30 13,764 1,311,709 55,710 Dec 14 06:18 PM Ajer Jeffrey Robert EVP, Chief Commercial Officer Aug 16 '23 Sale 90.00 5,000 450,000 60,804 Aug 17 03:57 PM FUCHS HENRY J President, Worldwide R&D Aug 10 '23 Sale 90.43 12,000 1,085,111 176,187 Aug 11 01:59 PM Guyer Charles Greg EVP, Chief Technical Officer Aug 09 '23 Sale 93.30 5,360 500,109 40,041 Aug 10 04:47 PM Davis George Eric EVP, Chief Legal Officer Aug 08 '23 Sale 89.42 11,000 983,662 69,474 Aug 09 07:08 PM BIENAIME JEAN JACQUES Chief Executive Officer Aug 08 '23 Sale 88.29 6,000 529,740 422,732 Aug 09 07:05 PM BIENAIME JEAN JACQUES Chief Executive Officer Aug 07 '23 Sale 88.10 4,000 352,400 428,732 Aug 09 07:05 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite